Natera (NASDAQ:NTRA) PT Raised to $150.00 at Leerink Partners

Natera (NASDAQ:NTRA) had its price target hoisted by equities research analysts at Leerink Partners from $140.00 to $150.00 in a research note issued on Thursday, Benzinga reports. The firm presently has an “outperform” rating on the medical research company’s stock. Leerink Partners’ price target suggests a potential upside of 19.53% from the stock’s previous close.

A number of other equities research analysts have also issued reports on the stock. Stephens restated an “overweight” rating and issued a $125.00 target price on shares of Natera in a research note on Friday, August 9th. Robert W. Baird increased their target price on Natera from $117.00 to $120.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. StockNews.com downgraded Natera from a “hold” rating to a “sell” rating in a report on Wednesday, August 28th. The Goldman Sachs Group raised their price objective on Natera from $125.00 to $140.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, TD Cowen boosted their target price on shares of Natera from $137.00 to $145.00 and gave the company a “buy” rating in a research note on Friday, August 9th. One research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $124.44.

Natera Stock Down 1.0 %

NASDAQ NTRA traded down $1.28 during trading hours on Thursday, hitting $125.49. The company had a trading volume of 97,549 shares, compared to its average volume of 1,338,109. The firm’s 50 day moving average is $122.85 and its 200 day moving average is $110.07. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.14 and a quick ratio of 4.01. Natera has a fifty-two week low of $36.90 and a fifty-two week high of $133.54. The company has a market capitalization of $15.41 billion, a price-to-earnings ratio of -40.22 and a beta of 1.53.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, August 8th. The medical research company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.39. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The business had revenue of $413.35 million for the quarter, compared to analyst estimates of $343.00 million. During the same period in the previous year, the company earned ($0.97) earnings per share. The company’s revenue for the quarter was up 58.1% compared to the same quarter last year. Sell-side analysts anticipate that Natera will post -1.96 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Solomon Moshkevich sold 549 shares of the stock in a transaction dated Monday, July 22nd. The shares were sold at an average price of $105.16, for a total value of $57,732.84. Following the completion of the transaction, the insider now owns 113,637 shares in the company, valued at $11,950,066.92. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other Natera news, insider Solomon Moshkevich sold 549 shares of the stock in a transaction on Monday, July 22nd. The stock was sold at an average price of $105.16, for a total transaction of $57,732.84. Following the completion of the transaction, the insider now directly owns 113,637 shares of the company’s stock, valued at approximately $11,950,066.92. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Jonathan Sheena sold 3,000 shares of Natera stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $125.67, for a total value of $377,010.00. Following the transaction, the insider now owns 57,432 shares in the company, valued at approximately $7,217,479.44. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 46,242 shares of company stock valued at $5,426,901. Company insiders own 7.60% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. IQ EQ FUND MANAGEMENT IRELAND Ltd acquired a new position in shares of Natera in the 3rd quarter worth $249,000. Creative Planning raised its holdings in Natera by 18.3% during the 3rd quarter. Creative Planning now owns 5,833 shares of the medical research company’s stock worth $740,000 after buying an additional 904 shares during the period. Exchange Traded Concepts LLC boosted its holdings in shares of Natera by 30.5% in the third quarter. Exchange Traded Concepts LLC now owns 12,064 shares of the medical research company’s stock worth $1,532,000 after buying an additional 2,821 shares during the period. CWM LLC increased its position in shares of Natera by 119.5% in the third quarter. CWM LLC now owns 15,441 shares of the medical research company’s stock worth $1,960,000 after acquiring an additional 8,406 shares in the last quarter. Finally, Connective Portfolio Management LLC raised its holdings in shares of Natera by 40.6% during the third quarter. Connective Portfolio Management LLC now owns 9,000 shares of the medical research company’s stock valued at $1,143,000 after acquiring an additional 2,600 shares during the period. Institutional investors and hedge funds own 99.90% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.